July 11, 2024
Synergyne ART Analytics Inc. and Cybera Revolutionize Fertility Treatment with AI-Driven Matris™ Test Advancements
(CALGARY, AB) July 11, 2024 — Synergyne ART Analytics Inc. and Cybera’s Applied Data Science Lab are thrilled to share the successful…
June 12, 2024
Synergyne ART Analytics Inc. and HoMu Health Ventures Forge a Strategic Partnership to Revolutionize Fertility Technology
Synergyne ART Analytics Inc. announces an official investment and operating partnership with HoMu Health Ventures to advance reproductive health technology. This collaboration focuses on commercializing Synergyne's innovative non-invasive diagnostic test, Matris™, designed to improve IVF outcomes by assessing endometrial receptivity before embryo transfer.
May 3, 2023
Synergyne ART Analytics Inc. and Cybera’s Applied Data Science Lab Join Forces to Advance Fertility Treatment, Artificial Intelligence in Medical Tech
Synergyne ART Analytics Inc. and Cybera’s Applied Data Science Lab are proud to announce their collaboration to advance fertility treatment and artificial intelligence/machine learning(AI/ML) within the medical technology (MedTech) industry.
March 7, 2023
Synergyne ART Analytics Inc. enters into a Memorandum of Understanding with HoMu Health Ventures
Steve Rowley, VP for Synergyne, states “The team at HoMu brings additional scientific knowledge, clinic relationships and proven commercialization expertise in developing advanced reproductive technologies which improve IVF outcomes.
April 4, 2022
Canadian Reproductive Tool for IVF Patients Expands Globally to Become First Fully AI Medtech of its Kind
Matris ™ by Synergyne ART Analytics Inc., enters the next phase to become the world’s first and only artificially intelligent fertility technology of its kind — opening the door for improved pregnancy rates for IVF patients everywhere. World-leading US fertility clinic and foremost research hub, Boston IVF, will take the tool across the border to validate the improvement in the IVF success rates achieved in Canada.